Joseph P Hagan
CIK 1465278 · Chief Executive Officer · last filed 2025-06-27
Joseph P Hagan is a Chief Executive Officer who has filed 72 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for RGLS, was dated Jun 27, 2025. Across all open-market trades the lifetime net is −$2.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $193.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$193.5K
4
72
-$1.95M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc. (RGLS) Delisted | Chief Executive Officer | 225,674 | $8.16 | $1.84M | $94.1K | 43 | 2025-06-27 |
| AUPH | Director | 12,233 | $15.82 | $193.5K | -$906.5K | 4 | 2023-05-23 |
| Zosano Pharma Corp (ZSAN) Delisted | Director | 22,500 | $0.56 | $12.5K | $0 | 8 | 2021-06-14 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Chief Business Officer | 13,026 | — | — | -$1.14M | 17 | 2015-02-05 |
Recent Filings
72 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-27 | Regulus Therapeutics Inc. (RGLS) Delisted | Disp (D) | −571,558 | $0 | EDGAR |
| 2025-01-31 | Regulus Therapeutics Inc. (RGLS) Delisted | Mixed | +50,000 | $54.3K | EDGAR |
| 2025-01-15 | Regulus Therapeutics Inc. (RGLS) Delisted | Sell (S) | −127,054 | -$160.5K | EDGAR |
| 2025-01-10 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | +280,750 | $378.1K | EDGAR |
| 2024-05-21 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-18 | Regulus Therapeutics Inc. (RGLS) Delisted | Sell (S) | −14,580 | -$17.4K | EDGAR |
| 2024-01-17 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | +30,000 | $0 | EDGAR |
| 2023-08-14 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-23 | AUPH | Mixed | +8,461 | -$2.9K | EDGAR |
| 2023-01-17 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |